SYDNEY, Jan. 7, 2015 /PRNewswire/ -- Novogen Limited
(ASX:NRT; NASDAQ:NVGN), an Australian/US
biotechnology company, today announced that it will hold a public
Briefing for shareholders and investors in New York on 18th February 2015 at 2
pm New
York time.
The briefing will be held at the Yale Club (Saybrook Room), 50
Vanderbilt Ave, Manhattan
(opposite Grand Central Terminal).
The main purpose of the Briefing is to provide an opportunity
for US shareholders to meet senior company executives and for the
investment community at large to better understand the Company's
intellectual property portfolio and commercial potential.
Dr Graham Kelly, Novogen Group
CEO and Executive Chairman, will present an overview of the
clinical and corporate strategies for the Novogen Group for
2015-2016.
Professor Gil Mor PhD MD of Yale Medical
School will present a talk entitled "Cantrixil: A Novel Therapy to Target Cancer
Stem Cells to Prevent Tumor Recurrence."
Dr Marc Symons PhD of the Feinstein Institute for Medical
Research at North Shore-LIJ will present a talk entitled
"Development of TRXE-009 for the Treatment of Brain Cancer."
Dr Andrew Heaton, Novogen VP Drug
Design and Manufacturing, and Mr Robert
Kennedy, Novogen VP Corporate Relations (US), also will be
in attendance.
The details of the Briefing are contained in the January edition
of the Novogen Newsletter released today and available on the
Company's website.
People interested in attending will need to confirm by
contacting prue.kelly@novogen.com
About Novogen Limited
Novogen is a public, Australian drug-development company whose
shares trade on both the Australian Securities Exchange ('NRT') and
NASDAQ ('NVGN'). The Novogen group includes US-based CanTx Inc, a joint venture company with
Yale University.
Novogen has two main drug technology platforms:
super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP
compounds have been designed to kill the full heterogeneity of
cells within a tumor, including the cancer stem cells. The
molecular target is a trans-membrane electron-transfer pump
mechanism oncogene that is common to all cancer cells. Cells die by
respiratory distress and mitochondrial disintegration.
The ATM compounds target the micro-filament component of the
cancer cell's cytoskeleton and have been designed to combine with
anti-microtubular drugs (taxanes, vinca alkaloids) to produce
comprehensive and fatal destruction of the cancer cell
cytoskeleton.
The Company pipeline comprises three SBP drug candidates
(TRXE-002, TRXE-009, TRXE-0025) and one ATM drug candidate
('Anisina').
Further information is available on our websites
www.novogen.com
For more information please contact:
Briefing
Contact
|
|
Prue Kelly
|
|
Prue.Kelly@novogen.com
|
|
|
|
Corporate Contact
|
Media Enquiries
|
Dr. Graham Kelly
|
Cristyn Humphreys
|
Executive Chairman & CEO Novogen
Group
|
Chief Operating Officer Novogen
Group
|
Graham.Kelly@novogen.com
|
Cristyn.Humphreys@novogen.com
|
+61 (0) 2 9472 4100
|
+61 (0) 2 9472 4111
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/novogen-to-conduct-shareholderinvestor-briefing-in-new-york-300017059.html
SOURCE Novogen Ltd